FAIM
GILD icon

Financial Advocates Investment Management’s Gilead Sciences GILD Stock Holding History

Financial Advocates Investment Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,239
Closed -$248K – 267
2025
Q2 		$248K Sell
2,239
-1,959
-47% -$208K 0.02% 542
2025
Q1 		$470K Sell
4,198
-4,541
-52% -$469K 0.03% 439
2024
Q4 		$807K Sell
8,739
-6,372
-42% -$574K 0.05% 351
2024
Q3 		$1.27M Buy
15,111
+665
+5% +$50.7K 0.07% 257
2024
Q2 		$991K Buy
14,446
+5,526
+62% +$369K 0.06% 294
2024
Q1 		$653K Buy
8,920
+729
+9% +$56.1K 0.04% 402
2023
Q4 		$664K Buy
8,191
+308
+4% +$24K 0.04% 369
2023
Q3 		$591K Buy
7,883
+282
+4% +$21.7K 0.04% 376
2023
Q2 		$586K Sell
7,601
-951
-11% -$75.8K 0.04% 366
2023
Q1 		$710K Sell
8,552
-2,243
-21% -$186K 0.05% 355
2022
Q4 		$927K Buy
10,795
+6,186
+134% +$490K 0.07% 307
2022
Q3 		$275K Sell
4,609
-5,295
-53% -$334K 0.02% 575
2022
Q2 		$612K Buy
9,904
+2,719
+38% +$168K 0.05% 359
2022
Q1 		$427K Buy
7,185
+2,845
+66% +$182K 0.03% 480
2021
Q4 		$321K Sell
4,340
-2,877
-40% -$198K 0.02% 616
2021
Q3 		$504K Buy
7,217
+2,198
+44% +$154K 0.03% 471
2021
Q2 		$347K Sell
5,019
-1,805
-26% -$121K 0.02% 568
2021
Q1 		$441K Buy
6,824
+88
+1% +$5.67K 0.03% 510
2020
Q4 		$393K Buy
6,736
+1,485
+28% +$89.6K 0.03% 495
2020
Q3 		$332K Buy
5,251
+430
+9% +$29.8K 0.03% 457
2020
Q2 		$371K Sell
4,821
-1,411
-23% -$108K 0.04% 416
2020
Q1 		$466K Buy
6,232
+2,621
+73% +$181K 0.07% 287
2019
Q4 		$235K Sell
3,611
-869
-19% -$56.6K 0.03% 454
2019
Q3 		$284K Sell
4,480
-471
-10% -$30.8K 0.03% 388
2019
Q2 		$334K Sell
4,951
-1,561
-24% -$103K 0.04% 358
2019
Q1 		$423K Sell
6,512
-1,635
-20% -$109K 0.05% 303
2018
Q4 		$509K Sell
8,147
-1,255
-13% -$87.7K 0.07% 241
2018
Q3 		$726K Buy
+9,402
New +$710K 0.08% 229
2018
Q1 		– Sell
-8,477
Closed -$607K – 503
2017
Q4 		$607K Buy
+8,477
New +$644K 0.08% 230

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Financial Advocates Investment Management's GILD Position: Q3 2025 in Review

Financial Advocates Investment Management sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 2,239 shares — an estimated $248K sold.

Financial Advocates Investment Management first reported a position in GILD in Q4 2017 and held it in 29 quarters. The position peaked at $1.27M in Q3 2024. 2,028 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

  • Financial Advocates Investment Management reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
  • Financial Advocates Investment Management sold 2,239 Gilead Sciences shares in Q3 2025, an estimated $248K.
  • Financial Advocates Investment Management first reported a position in Gilead Sciences in Q4 2017 and held it in 29 quarters.
  • Financial Advocates Investment Management's Gilead Sciences position peaked at $1.27M in Q3 2024.
  • 2,028 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on Financial Advocates Investment Management's 13F filing for Q3 2025, filed 6 Nov 2025.